Confirmed RECIST v1.1 ORR favored varegacestat (56% vs 9%; P<.0001), with exploratory median best tumor-volume change of −83% ...

BELLA (NCT06906341) has completed enrollment testing triplet strategies such as adding bevacizumab and expanding evaluation ...

Median overall survival exceeded SEER benchmarks by 2 months in metastatic NSCLC and 8 months in de novo metastatic breast ...

Deborah Stephens, DO, explains why she prefers continuous BTKi vs time-limited options for patients with high-risk del(17p) ...

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...

Deborah Stephens, DO, discusses patient-reported outcomes and quality of life reports from the SEQUOIA (zanubrutinib) and ...

The BTK inhibitors zanubrutinib (Brukinsa) and acalabrutinib (Calquence) were explored in chronic lymphocytic patients in the ...

Tanya Siddiqi, MD, highlights long-term safety outcomes with first-line zanubrutinib (Brukinsa) in patients with chronic ...

Deborah Stephens, DO, discusses long-term efficacy outcomes with targeted therapies in the treatment of patients with chronic ...

In the SEQUOIA trial, the BTK inhibitor zanubrutinib (Brukinsa) was delivered as a continuous dose in frontline chronic ...

Tanya Siddiqi, MD, discusses long-term outcomes with first-line zanubrutinib (Brukinsa) in patients with high-risk chronic ...

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk ...